The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Tamara Sauri
No Relationships to Disclose
 
Antonio Cubillo
No Relationships to Disclose
 
Carlos López-López
Consulting or Advisory Role - Amgen; Merck; Roche; Sanofi
Research Funding - Amgen; Merck; MSD; Roche; Sanofi
 
Pilar Garcia Alfonso
No Relationships to Disclose
 
Maen A. Hussein
Stock and Other Ownership Interests - Celgene (I)
Honoraria - AMAG Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Speakers' Bureau - AMAG Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Sarah Cannon Research Institute (Inst)
 
M. Luisa Limon
No Relationships to Disclose
 
Andres Cervantes
Honoraria - Roche
Consulting or Advisory Role - Roche
Speakers' Bureau - Roche
Research Funding - Genentech; Roche
 
Clara Montagut
No Relationships to Disclose
 
Cristina Santos
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Merck; Roche
 
Alberto Bessudo
Honoraria - HERON; Takeda
Consulting or Advisory Role - HERON; Takeda
Research Funding - Amgen (Inst); Celgene (Inst); EmR (Inst); Halozyme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer
 
Manuel R. Modiano
No Relationships to Disclose
 
Veerle Moons
No Relationships to Disclose
 
Johannes Andel
Consulting or Advisory Role - Gilead Sciences; Lilly; Merck; Roche
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
 
Andre Van Der Westhuizen
Research Funding - Amgen; Bristol-Myers Squibb; Merck; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Leslie M. Samuel
Honoraria - Eisai
Consulting or Advisory Role - SERVIER
Research Funding - Lilly; Merck; MOLOGEN; Roche
 
Oliver Krieter
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Simona Rossomanno
Employment - Roche
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)